Dynavax Technologies | DVAX - Прибыль до налогообложения



Прибыль до налогообложения Изменить Дата
AbbVie USD 5.57B 2.9B 2026-03
Adma Biologics USD 57.13M 4.47M 2026-03
Agenus USD -10.61M 263.52M 2025-12
Amgen USD 1.51B 2.41B 2025-12
AstraZeneca USD 4.81B 894M 2026-06
Biogen USD 377.7M 433.7M 2026-03
BioMarin Pharmaceutical USD 141.2M 168.36M 2026-03
Bristol-Myers Squibb USD 1.47B 1.64B 2025-12
Gilead Sciences USD 2.08B 1.56B 2025-12
Glaxosmithkline GBP 2.14B 312M 2026-03
Merck USD 3.42B 3.32B 2025-12
Minerva Neurosciences USD 22.51M 30.74M 2024-09
Nektar Therapeutics USD -34.7M 2.35M 2025-12
Neurocrine Biosciences USD 246.8M 7.4M 2026-03
Novartis USD 4.27B 430M 2026-06
Pfizer USD 5.18B 6.82B 2026-03
Regeneron Pharmaceuticals USD 1.04B 719.6M 2025-12
Roche Holding CHF 11.17B 6.38B 2026-06
Sarepta Therapeutics USD 343.17M 750.85M 2026-03
TG Therapeutics USD 20.36M 24.73M 2026-03
Vertex Pharmaceuticals USD 1.25B 78.1M 2026-03